News

Using Cala Health’s non-invasive therapeutic device Cala Trio for 40 minutes twice daily effectively helped to reduce hand tremors within three months, results from a clinical study show. The results, “Study Design, Baseline Demographics, and Interim Results from the Prospective Study for Symptomatic Relief of Essential…

Oral treatment with tavapadon eased motor symptoms and was well-tolerated by patients with early-stage Parkinson’s, according to data from a Phase 2 clinical trial. Cerevel Therapeutics’ tavapadon (formerly known as PF-06649751) is a selective partial agonist of the dopamine D1 and D5 receptors, and is…

The Parkinson’s Foundation’s fourth annual Spanish-language conference, set for Oct. 19 in Norwalk, California, will provide the latest information about Parkinson’s disease treatment and management. Called “Hacia Adelante: Navegando el Mar del Parkinson’s” (“Forward: Sailing the Parkinson’s Sea”), the free conference is for patients, families, and…

Patients with Parkinson’s disease who were treated with Accordion Pill Carbidopa/Levodopa (AP-CD/LD) tolerated a higher dose of levodopa and experienced less variability in plasma levels of this standard therapy than those on Sinemet. Those are the top-line results from a Phase 3 clinical trial and data from a…

Continuous delivery of carbidopa/levodopa (CD/LD) with ND0612 under the skin led to quick improvement of clinical status and better quality of life for  patients with advanced Parkinson’s disease, according to patient-reported outcomes from a Phase 2 clinical trial. Now, a global Phase 3 study named BouNDless (NCT04006210) is…

With the aim of opening entirely new avenues in Parkinson’s disease research and care, The Michael J. Fox Foundation (MJFF) has announced a $10 million contest to drive development of an imaging tracer that would be used to see alpha-synuclein protein in the living brain. Called the “…

The small molecule IRL752 may be a safe and effective treatment, which could potentially help manage symptoms known to be unresponsive to levodopa, for people with Parkinson’s disease dementia, results from a Phase 2a clinical study suggest. Preliminary data suggests treatment with IRL752 could reduce apathy, as…

Gocovri (amantadine) extended release capsules work to help lessen dyskinesia, or involuntary muscle movement, and off episodes in Parkinson’s, but special care needs to be given elderly patients with poorer kidney function, according to data presented by Adamas Pharmaceuticals, the treatment’s developer, at a science conference. Renal…

A Phase 2 clinical trial testing the safety and effectiveness of the gene therapy VY-AADC02 in people with advanced Parkinson’s disease is recruiting patients at select sites across the U.S., according to a release by one such site. Hackensack University Medical Center is among the 17 institutions across…

People with Parkinson’s disease who have a specific mutation in the LRRK2 gene may be 10 times more likely to develop leukemia, and twice as likely to have colon cancer, researchers report. The researchers say this particular patient population should be closely monitored and screened for the early…